» Articles » PMID: 33189613

Exploring the Multifocal Therapeutic Approaches in COVID-19: A Ray of Hope

Overview
Date 2020 Nov 15
PMID 33189613
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The ongoing global pandemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is marked as one of the most challenging infectious diseases in the history of mankind with affliction of ~29,737,453 confirmed cases globally. Looking at the present scenario where there is a parallel increment in curve with time, there is an utmost emergency to discover a perennial solution to this life-threatening virus which has led the Human race in an unusual state of affair. The entire health care fraternity is engaged in endeavouring an ultimate way out to hit this pandemic but no such research made till now has been approved yet, to have the potential to bring an end to this fatal situation. Although a few possible treatment choices exist at the moment yet the requirement to search for a still better therapeutic option remains persistent. Global laboratories are working day and night in search for an effective vaccine, many are undergoing clinical trials but their commercialization is no less than a year away. The present review highlights the current potential therapies viz., vaccines, immunotherapies, convulsant plasma therapies, corticosteroids, antithrombotic, intravenous immunoglobulins, nocturnal oxygen therapy etc. that may prove beneficial in attenuating the pandemic situation. However, comparison and presentation of collective data on the therapeutic advancements in mitigating the pandemic situation needs further clinical investigations in order to prove boon to mankind.

Citing Articles

Correlation of covid-19 and Guillain-Barré syndrome: A Mechanistic Perspective.

Sharma V, Chhabra T, Singh T Obes Med. 2023; 40:100493.

PMID: 37131407 PMC: 10091783. DOI: 10.1016/j.obmed.2023.100493.

References
1.
Arnaldez F, ODay S, Drake C, Fox B, Fu B, Urba W . The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020; 8(1). PMC: 7211108. DOI: 10.1136/jitc-2020-000930. View

2.
Zha L, Li S, Pan L, Tefsen B, Li Y, French N . Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020; 212(9):416-420. PMC: 7262211. DOI: 10.5694/mja2.50577. View

3.
Chen Y, Liu Q, Guo D . Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4):418-423. PMC: 7167049. DOI: 10.1002/jmv.25681. View

4.
Moorlag S, van Deuren R, van Werkhoven C, Jaeger M, Debisarun P, Taks E . Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Rep Med. 2020; 1(5):100073. PMC: 7405881. DOI: 10.1016/j.xcrm.2020.100073. View

5.
Calabrese E, Dhawan G, Kapoor R, Kozumbo W . Radiotherapy treatment of human inflammatory diseases and conditions: Optimal dose. Hum Exp Toxicol. 2019; 38(8):888-898. DOI: 10.1177/0960327119846925. View